


Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



OMB # 0925-0648

Expiration Date: 6/30/2024

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

Thank you for attending the 11th Annual Meeting of T32 Trainees! Please take a few minutes to evaluate this meeting. Our goal is to obtain feedback so that we can improve the next meeting.


Responses are anonymous. If you would like a response, please include your contact details at the end of the survey or email us at bpca@infinityconferences.com.

Please select the choice below that best describes your role at this meeting.

- Pediatric Clinical Pharmacology Fellow
- Other Pediatric Fellow
- Adult Clinical Pharmacology Fellow
- Other Adult Fellow
- Former Fellow
- PI/Program Director
- Other (FDA, NIH, etc.)

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



Virtual Meeting Logistics

Were you satisfied with the frequency and quality of pre-meeting communications regarding virtual participation?

Yes

No

Additional Comments

On a scale of 1 to 5 with 5 being the best, how would you rate the quality of support received during the virtual meeting?

1 (poor)

5 (excellent)


N/A

<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Additional Comments

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development



Agenda Feedback

On a scale of 1 to 5, with 5 being the best, how would you rate the following sessions on September 19:

Leveraging MPRINT Resources to Further T32 Training and Research

1 (poor)	2	3	4	5 (excellent)	N/A
★	★	★	★	★	○


Additional Comments


Functions and Value of Becoming a Diplomate of ABCP by Examination

1 (poor)	2	3	4	5 (excellent)	N/A
★	★	★	★	★	○

Additional Comments

Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute of Child Health and Human Development



Agenda Feedback

On a scale of 1 to 5, with 5 being the best, how would you rate the following session on September 20:

T32 to K23 to Leadership: Career Trajectory of a Former Fellow

1 (poor)

2

3

4

5 (excellent)

N/A



Additional Comments

On a scale of 1 to 5, with 5 being the best, how would you rate the panel discussion on September 20?

1 (poor)

2

3

4

5 (excellent)


N/A



Additional Comments

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



Agenda Feedback

Please provide your feedback on the breakout sessions.

Please provide your feedback on the fellow presentations.

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



General Feedback

On a scale of 1 to 5, with 5 being the best, what is your overall rating of the Eleventh Annual Meeting of T32 Trainees?

1 (poor)

2

3

4

5 (excellent)



What is the main reason for your rating?

Please provide any additional comments regarding the virtual meeting format, agenda content, or logistical support. Include any suggestions for next year's meeting.

Name and Email Address (Optional)

Please provide your email address if you'd like a response to your comments.

Name

Email Address